Clinical Trials Education Center

woman-at-doctors-appointment

About Clinical Trials

Clinical trials for pulmonary fibrosis treatment are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people. Clinical trials for pulmonary fibrosis treatment produce the best data available for health care decision making.

The purpose of clinical trials is research, so the studies follow strict scientific standards. These standards protect patients and help produce reliable study results.

To read more, download our booklet below.

Find a Clinical Trial

The PFF Clinical Trial Finder is a comprehensive list of clinical trials for pulmonary fibrosis related conditions.

pipeline

Drug Development Pipeline for PF and IPF

In the PF Drug Development Pipeline you can learn about the latest in drug development for PF-related conditions. Use the filters on the left-hand side to narrow results by study phase, intervention type, condition, and more.

Featured Trials

 

Patients diagnosed with PF or ILD, Lung transplant recipients who have had PF or ILD, Caregivers and/or biological family members (parent, child, full/half sibling) of patients with PF or ILD—including those who have passed away (participants must be 18 or older and live in the U.S.)

 

PFF Community Registry

Study ID: NCT05382572
Intervention: Data collection, observational/monitoring
Sponsor: Pulmonary Fibrosis Foundation; University of Michigan
Contact: registry@pulmonaryfibrosis.org; pffr-dcc-pm@umich.edu

Idiopathic Pulmonary Fibrosis

The Genetics of PF

Study ID: NCT03478553
Intervention: Blood or biological sample collection, survey/questionnaire
Sponsor: University of Colorado, Denver
Contact: rachel.warren@cuanschutz.edu; 303.724.8569

Interstitial Lung Diseases

129Xe Gas Exchange MRI to Visualize Regional Therapy Response in ILD

Study ID: NCT04855305
Trial Phase
: Phase 2
Intervention
: Hyperpolarized 129Xe
Sponsor: Duke University
Contact: jennifer.korzekwinski@duke.edu; 919.681.7362 and cody.blanton@duke.edu; 919.668.7575

Pulmonary Sarcoidosis

Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis

Study ID: NCT05415137
Trial Phase
: Phase 3
Intervention
: Intravenous (IV) injection
Sponsor: aTyr Pharma, Inc.
Contact: efzofit@cssienroll.com; 877.596.6699

The PFF Community Registry

The Pulmonary Fibrosis Foundation is leading the fight by funding promising research and we need your help. 

One of our key research programs is the PFF Community Registry. We invite eligible participants to join by completing a series of simple surveys. Your survey responses will be used by researchers to better understand how PF and ILD progress over time, respond to treatments, and how the diseases affect individuals. The more individuals who join and provide responses, the closer we come to a cure.

Eligible participants include:

  • Patients living with PF and ILD
  • Lung transplant recipients who have had PF or ILD
  • Caregivers and biological family members of patients with PF or ILD, including those who have passed away

Enrolling in the PFF Community Registry is entirely online. All you need is internet access. Learn more about this groundbreaking program by visiting the PFF Community Registry homepage

map showing people all over the United States

Phases of Clinical Trials

Clinical trials investigate dosage, safety, efficacy and potential outcomes of drugs or treatments in disease-specific populations through controlled trials. There are typically three stages or phases of clinical trials that must be performed before a drug or treatment may be submitted to regulatory agencies (ie: U.S. Food & Drug Administration) for approval. Prior to commencing a clinical trial, a drug must have demonstrated safety and efficacy in a laboratory model.

Phase 1 Clinical Trials

Phase 1

Researchers test a new drug or treatment in a small group of people (usually 20-100 volunteers) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. Doses start small and increase in different patient groups until the desired effect of the treatment is observed or side effects of the treatment become too severe.

Phase 2 Clinical Trials

Phase 2

The drug or treatment is given to a larger group of people (up to several hundred volunteers) to see if it is effective and to further evaluate its safety. Most Phase 2 studies have randomized control (placebo) groups and treatment groups. Most of these trials are “double-blind” which means that neither the patients nor the researchers know whether the patient is receiving the treatment or placebo.

Phase 3 Clinical Trials

Phase 3

The drug or treatment is given to large groups of people (several hundred to thousands of volunteers) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments (or placebo), and collect information that will allow the drug or treatment to be used safely. Phase 3 trials are also randomized and most are double-blind.

Phase 4 Clinical Trials

Phase 4

The drug or treatment has been FDA approved for marketing. These studies can include post-market requirement and commitment studies that are required of or agreed to by the study sponsor. Phase 4 trials gather additional information about a drug's safety, efficacy, or optimal use.

Clinical Trials FAQs

What is a clinical trial?
What types of therapies are being studied?
What are the types of clinical trials?
What types of research are being performed in clinical trials for pulmonary fibrosis treatment?
What types of interventions are being used in clinical trials?